Foghorn Therapeutics's three largest insider shareholders as of September 29, 2026 are Adrian Gottschalk (Chief Executive Officer, 511.70K shares), Adrian Gottschalk (Chief Executive Officer, 511.70K shares), Carl Decicco (Chief Scientific Officer, 362.71K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Adrian Gottschalk | Chief Executive Officer | 0 | 511,704 | 511,704 | 37.0% | 13 Apr, 2026 |
| 2 | Carl Decicco | Chief Scientific Officer | 362,707 | 0 | 362,707 | 26.3% | 13 Dec, 2021 |
| 3 | Cigall Kadoch | Director, TenPercentOwner | 295,000 | 0 | 295,000 | 21.4% | 15 Dec, 2021 |
| 4 | Steven F. Bellon | Chief Scientific Officer | 101,957 | 0 | 101,957 | 7.4% | 11 Sep, 2024 |
| 5 | Fanny Cavalie | Chief Strategy/Bus Ops Officer | 75,992 | 0 | 75,992 | 5.5% | 12 Mar, 2024 |
| 6 | Simba Gill | Director | 34,061 | 0 | 34,061 | 2.5% | 14 Sep, 2022 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 24 Jun, 2026 | Scott Biller | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Simba Gill | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Ian F Smith | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Stuart Duty | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Michael Mendelsohn | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | B Lynne Parshall | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Thomas J. Jr. Lynch | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Neil Gallagher | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 24 Jun, 2026 | Douglas G. Cole | Director | Acquired A | 28,000 | $4.08 | $114.24K | 28,000 | Direct |
| 09 Apr, 2026 | Adrian Gottschalk | Chief Executive Officer | Disposed G | 47,497 | $0.00 | $0 | 0 | Indirect |
| 09 Apr, 2026 | Adrian Gottschalk | Chief Executive Officer | Acquired G | 47,497 | $0.00 | $0 | 211,704 | Indirect |
| 10 Apr, 2026 | Adrian Gottschalk | Chief Executive Officer | Disposed G | 59,208 | $0.00 | $0 | 240,792 | Indirect |
| 10 Apr, 2026 | Adrian Gottschalk | Chief Executive Officer | Acquired G | 59,208 | $0.00 | $0 | 270,912 | Indirect |
| 23 Feb, 2026 | Ryan D Maynard | Chief Financial Officer | Acquired A | 400,000 | $5.75 | $2.30Mn | 400,000 | Direct |
| 05 Feb, 2026 | Adrian Gottschalk | Chief Executive Officer | Acquired A | 1,075,000 | $5.23 | $5.62Mn | 1,075,000 | Direct |
| 30 Jan, 2026 | Carlos Costa | Chief People Officer | Acquired A | 230,000 | $5.71 | $1.31Mn | 230,000 | Direct |
| 30 Jan, 2026 | Steven F. Bellon | Chief Scientific Officer | Acquired A | 300,000 | $5.71 | $1.71Mn | 300,000 | Direct |
| 30 Jan, 2026 | Michael Lacascia | Chief Legal Officer | Acquired A | 295,000 | $5.71 | $1.68Mn | 295,000 | Direct |
| 30 Jan, 2026 | Anna Rivkin | Chief Business Officer | Acquired A | 165,000 | $5.71 | $942.15K | 165,000 | Direct |
| 30 Jan, 2026 | Alfonso Quintas Cardama | Chief Medical Officer | Acquired A | 300,000 | $5.71 | $1.71Mn | 300,000 | Direct |